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LESSONS LEARNED
• The combination of standard dose abiraterone acetate and BEZ235, a pan-class I PI3K and mTORC1/2 inhibitor, was poorly toler-
ated in men with progressive mCRPC.
• Although the clinical development of BEZ235 has been discontinued in prostate cancer, agents that more selectively target PI3K-
AKT-mTOR signaling may have a more favorable therapeutic index and should continue to be explored.
ABSTRACT
Background. Androgen receptor (AR) and phosphatidylinositol-
3 kinase (PI3K) signaling are two commonly perturbed path-
ways in prostate cancer. Preclinical data have shown that
the two pathways compensate for each other when one is
inhibited, and combined inhibition of AR and PI3K signaling
may be a viable strategy to prevent or overcome castration
resistance.
Methods. This phase I study evaluated the safety and tolerabil-
ity of abiraterone acetate and prednisone combined with
BEZ235, a dual PI3K and mTORC1/2 inhibitor, in men with pro-
gressive metastatic castration resistant prostate cancer
(mCRPC) who have not received prior chemotherapy.
Results. Six patients (n5 6) were treated at the starting dose
level of abiraterone acetate 1,000 mg with prednisone 5 mg
twice daily and BEZ235 200 mg twice daily in a 31 3 dose
escalation design. The study was terminated early because
three of the six patients (50%) experienced dose-limiting
toxicities: grade 3 mucositis, grade 3 hypotension, and grade
4 dyspnea and pneumonitis. All six patients had previously
progressed on abiraterone/prednisone. The median treat-
ment duration was 27 days (range: 3–130 days). No
prostate-specific antigen (PSA) decline or objective response
were observed.
Conclusion. The combination of standard-dose abiraterone/
prednisone with BEZ235 200 mg twice daily was poorly tol-
erated in patients with mCRPC. The on-target and off-target
effects of dual PI3K and mTORC inhibition likely contributed
to the unacceptable toxicity profile. The Oncologist 2017;
22:503–e43
DISCUSSION
AR signaling and PI3K-AKT-mTOR signaling are among the most
common aberrant pathways found in advanced prostate can-
cer and are implicated in the development and maintenance
of castration resistant disease. Preclinical prostate cancer mod-
els have shown crosstalk and cross-regulation between the
two pathways, and enhanced tumor control with combination
strategies that co-inhibit AR and PI3K-AKT-mTOR signaling.
We report results of a phase I study evaluating the safety
and tolerability of standard dose abiraterone acetate
(1,000 mg daily with prednisone 5 mg b.i.d.) combined with
BEZ235, a potent dual pan-class I PI3K and mTORC1/2 inhibi-
tor, in patients with progressive mCRPC. The original study
design planned to determine the maximum tolerated dose
(MTD) of the combination during 31 3 dose escalation, fol-
lowed by a dose expansion phase to assess efficacy. The study
protocol specified that if >1 of 3 or >2 of 6 patients experi-
ence a dose-limiting toxicity (DLT) at dose level 1, the study
would be terminated. One of the first three patients accrued
experienced a DLT at dose level 1 (abiraterone/prednisone
plus BEZ235 200 mg b.i.d.), and three more patients were
accrued at dose level 1 (Table 1). Two of the last three
patients also experienced DLT, and the study was terminated
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Clinical Trial Results
due to lack of safety as specified by study protocol. The
median age of the patients was 71 years (range: 59–75 years).
The majority of patients (83.3%) had Gleason 8–10 disease.
All patients had bone metastases with or without nodal
metastasis; no patients had visceral metastases. All patients
had previously progressed on abiraterone.
The combination of standard dose abiraterone acetate and
BEZ235 200 mg b.i.d. was poorly tolerated. The median treat-
ment duration was 27 days (range: 3–130 days). The most com-
mon adverse events were oral mucositis (83.4%), diarrhea
(66.7%), nausea (50.0%), anorexia (50.0%), weight loss (50.0%),
and musculoskeletal pain (50.0%). The DLTs experienced by
patients (n5 3, 50%) were grade 3 mucositis, grade 3 hypoten-
sion, and grade 4 dyspnea and pneumonitis. Five patients
(83%) came off study because of study-related adverse events,
and one patient came off study due to disease progression. No
patient achieved any level of PSA decline (Fig. 1). The best radi-
ographic response in two patients was stable disease. The clini-
cal development of BEZ235 as a potential therapy for prostate
cancer has been discontinued.
Table 1. Dose-limiting toxicities
Dose
level
Dose of drug:
abiraterone
acetate
Dose of drug:
BEZ235
Number of
patients
enrolled
Number of
patients
evaluable
for toxicity
Number of
patients with
a dose-limiting
toxicity
Dose-limiting
toxicities
information
1 1,000 mg
daily
200 mg twice
daily
6 6 3 Grade 3 mucositis
(patient 1)
Grade 3
hypotension
(patient 5)
Grade 4 dyspnea
and pneumonitis
(patient 6)
Figure 1. Study schema. †, Phase 1 abiraterone dose was 1,000 mg daily with prednisone 5 mg b.i.d. and BEZ235 at MTD. ‡, Phase 2 start-
ing dose was abiraterone 1,000 mg daily with prednisone 5 mg b.i.d. and BEZ235 at MTD. §, If>1 of 3 or 2 of 6 patients experienced a
dose-limiting toxicity at dose level 1, the study would be terminated.
Abbreviations: BL, baseline; BID, twice daily; MTD, maximum tolerated dose; mTOR, mechanistic target of rapamycin; ORR, objective
response rate; PFS, progression-free survival; PI3K, phosphoinositide 3-kinase; PSA, prostate-specific antigen; W12, week 12.
TRIAL INFORMATION
Disease Prostate Cancer
Stage of disease/treatment Metastatic/Advanced
Prior Therapy No designated number of regimens
Type of study Phase I/II
Primary Endpoint Safety and feasibility
Secondary Endpoint Pharmacokinetics studies were not performed because the study was terminated early.
Additional Details of Endpoints or Study Design
The original study design planned to determine the MTD of the combination of abiraterone acetate and BEZ235 during 31 3
dose escalation (phase I), followed by a dose expansion phase to assess efficacy (phase II). The primary endpoint of the phase I
study was to determine the safety and feasibility of combining BEZ235 and abiraterone acetate. The primary endpoint of the
phase II study was PSA response rate, by >50%, at 12 weeks. The study protocol specified that if >1 of 3 patients or >2 of 6
patients experience a dose-limiting toxicity (DLT) at dose level 1, the study would be terminated (Fig. 2).
Investigator’s Analysis Poorly tolerated/not feasible
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DRUG INFORMATION
Drug 1
Generic/Working name Abiraterone acetate
Trade name Zytiga
Company name Janssen Biotech
Drug type Small molecule
Dose milligrams (mg) per flat dose
Route oral (p.o.)
Schedule of Administration 1,000 mg daily (given with prednisone 5 mg twice daily)
Drug 2
Generic/Working name BEZ235
Trade name N/A
Company name Novartis
Drug type Small molecule
Drug class PI3 kinase
Dose milligrams (mg) per flat dose
Route oral (p.o.)
Schedule of Administration 200 mg twice daily
PRIMARY ASSESSMENT METHOD
Control Arm: Prostate
Number of patients screened 13
Number of patients enrolled 6
Number of patients evaluable for toxicity 6
Number of patients evaluated for efficacy 2
Evaluation method RECIST v1.1 and PCWG2
Response assessment SD n5 2 (100%)
(Median) duration assessments duration of treatment 27 days
PATIENT CHARACTERISTICS
Number of patients, male 6
Number of patients, female 0
Stage Metastatic, castration resistant
Age Median (range): 71 years (59–75 years)
Number of prior systemic therapies Median (range): 2 (1–3)
Performance status: ECOG 0 — 4
1 — 2
2 —
3 —
unknown —
Cancer types or histologic subtypes Prostate 6
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ADVERSE EVENTS
All Cycles
Name *NC/NA 1 2 3 4 5 All Grades
Mucositis oral 16% 17% 50% 17% 0% 0% 84%
Diarrhea 33% 50% 17% 0% 0% 0% 67%
Nausea 50% 33% 17% 0% 0% 0% 50%
Anorexia 50% 17% 33% 0% 0% 0% 50%
Weight loss 50% 50% 0% 0% 0% 0% 50%
Investigations - Musculoskeletal pain 50% 17% 33% 0% 0% 0% 50%
Fatigue 67% 33% 0% 0% 0% 0% 33%
Rash maculopapular 66% 17% 17% 0% 0% 0% 34%
Hypotension 83% 0% 0% 17% 0% 0% 17%
Dyspnea 83% 0% 0% 0% 17% 0% 17%
Pneumonitis 83% 0% 0% 0% 17% 0% 17%
Investigations - Malaise 83% 17% 0% 0% 0% 0% 17%
Dyspepsia 83% 17% 0% 0% 0% 0% 17%
Investigations - Abdominal bloating 83% 17% 0% 0% 0% 0% 17%
Vomiting 83% 17% 0% 0% 0% 0% 17%
Dysgeusia 83% 17% 0% 0% 0% 0% 17%
Anal mucositis 83% 17% 0% 0% 0% 0% 17%
Investigations - Sore throat 83% 17% 0% 0% 0% 0% 17%
Epistaxis 83% 17% 0% 0% 0% 0% 17%
Skin hyperpigmentation 83% 17% 0% 0% 0% 0% 17%
Investigations - Extremity weakness 83% 17% 0% 0% 0% 0% 17%
Photosensitivity 83% 17% 0% 0% 0% 0% 17%
Investigations - Hemoptysis 83% 17% 0% 0% 0% 0% 17%
Platelet count decreased 83% 17% 0% 0% 0% 0% 17%
Serum amylase increased 83% 17% 0% 0% 0% 0% 17%
Hypocalcemia 83% 17% 0% 0% 0% 0% 17%
Adverse Events Legend
*No Change from Baseline/No Adverse Event
All adverse events that are at least probably related to study therapy, graded according to National Cancer Institute Common Terminology Criteria
for Adverse Events (CTCAE) v4.0.
SERIOUS ADVERSE EVENTS
Name Grade Attribution
Dyspnea 4 Possible
Pneumonitis 4 Possible
Serious Adverse Events Legend
Grade 4 dyspnea and pneumonitis occurred in the same patient.
DOSE-LIMITING TOXICITIES
Dose
level
Dose of drug:
abiraterone
acetate
Dose of
drug:
BEZ235
Number of
patients
enrolled
Number of
patients
evaluable
for toxicity
Number of
patients with
a dose-limiting
toxicity
Dose-limiting
toxicities
information
1 1,000 mg
daily
200 mg
twice daily
6 6 3 Grade 3 mucositis (patient 1)
Grade 3 hypotension (patient 5)
Grade 4 dyspnea and
pneumonitis (patient 6)
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In this phase I study of the combination of abiraterone/
prednisone plus BEZ235, combination therapy was found to be
intolerable. The PI3K (phosphoinositide 3-kinase) pathway is a
major driver of cancer progression in different malignancies.
Genomic aberrancy in the PI3K pathway is present in approxi-
mately 60% of mCRPC, and PI3K signaling has been identified
as a major mechanism of resistance in mCRPC [1, 2]. Preclinical
work from different groups has shown cross-regulation
between AR signaling and PI3K-AKT-mTOR signaling [3–5]. Fur-
thermore, combined inhibition of AR signaling and PI3K-AKT-
mTOR signaling has been shown to augment anti-cancer activ-
ity, particularly in models of prostate cancer with PTEN-loss
[3–5]. This led to the hypothesis that co-inhibition of these two
interconnected pathways may be a viable strategy to prevent
or overcome resistance in patients with CRPC.
Clinical trials of allosteric mTOR inhibitors in men with
advanced prostate cancer have demonstrated limited clinical
activity [6, 7]. This was thought to be due in part to the activa-
tion of AKTand led to the development of strategies that target
upstream of PI3K-AKT-mTOR signaling. Here, we report the first
study designed specifically to target androgen synthesis inhibi-
tion in combination with targeting PI3K signaling in mCRPC. In
this study, the combination of standard dose abiraterone ace-
tate (1,000 mg daily with prednisone 5 mg b.i.d.) with BEZ235,
a potent dual pan-class I PI3K and mTORC1/2 inhibitor was
evaluated (Figure 1). The combination was found to be poorly
tolerated, and dose escalation and cohort expansion was not
possible.
Six patients were accrued at dose level 1. The median age
of the patients was 71 years. The majority of patients (83.3%)
had Gleason 8–10 disease (Table 2). All patients had bone
metastasis with or without nodal metastasis; no patients had
visceral metastasis. The median number of prior therapy for
mCRPC was 2 (range: 1–3). All patients had previously pro-
gressed on abiraterone and were abiraterone-resistant. All
patients were chemotherapy-naive (Table 1).
The median treatment duration was 27 days (range: 3–
130 days). The most common adverse events were grade 1–
2 oral mucositis (66.7%), diarrhea (66.7%), nausea (50.0%),
anorexia (50.0%), weight loss (50.0%), and musculoskeletal
pain (50.0%). Three patients (50%) experienced DLT: grade 3
mucositis, grade 3 hypotension, and grade 4 dyspnea and
pneumonitis (Table 3). Five patients (83%) came off study
due to study-related adverse events, and one patient came
off study due to disease progression (Table 4). Of the three
patients who received study therapy for at least 1 month
(range: 38–130 days), none achieved any level of PSA
decline (Figure 2). The best radiographic response in two
patients was stable disease.
Mucositis, anorexia, and weight loss are adverse events
previously observed with PI3K-AKT-mTOR pathway inhibition
and may represent a class effect of targeting the PI3K path-
way. These adverse events were observed to a greater
extent than anticipated. BEZ235 was administered in suspen-
sion, after sachets of the drug were dissolved in approxi-
mately 200 mL of water; therefore, the increased rate of
mucositis observed may be related to higher drug exposure
and absorption in the oral mucosa. All patients enrolled
received maximal supportive care; therefore, our findings
demonstrate an extremely low likelihood that pan-PI3K and
mTORC1/2 inhibition can be achieved at the dose adminis-
tered. It is likely that adverse events were contributed by
off-target effects as well as on-target effects from inhibiting
all class I PI3K isoforms in addition to mTORC1/2 inhibition,
irrespective of their role in tumorigenesis. Based on these
findings as well as findings from another study with this
agent (NCT01634061, unpublished, but registered at Clinical-
Trials.gov), clinical development of BEZ235 as a potential
therapy for prostate cancer was discontinued. Of note, the
development of BEZ235 has also been discontinued for renal
cell carcinoma (RCC) due to high incidence of DLTs seen in
a phase Ib study of BEZ235 monotherapy in advanced RCC
patients [8].
Metastatic castration resistant prostate cancer that has
progressed despite abiraterone therapy is a challenge for
drug development as no agent other than docetaxel chemo-
therapy has shown consistent clinical activity in this setting
[9]. The rationale for targeting the PI3K-AKT-mTOR pathway
in mCRPC remains sound, however, and distinct agents that
may have a more favorable therapeutic index should con-
tinue to be explored. Agents targeting specific PI3K isoforms
may be better tolerated and achieve greater therapeutic effi-
cacy [10], and several isoform-specific PI3K inhibitors are cur-
rently under investigation as monotherapy or as combination
therapy in advanced solid tumors in early phase clinical trials
[11]. Furthermore, mTOR inhibitors that compete with the
ATP-binding site are currently under clinical development,
including the combination of enzalutamide with a dual ATP-
competitive mTOR and DNA-PK inhibitor, CC-115 in men
with abiraterone- and enzalutamide-naive progressive mCRPC
(NCT02833883) [12].
It remains to be determined what combination of AR and
PI3K pathway inhibition will be both tolerable and clinically
active. The combination of enzalutamide with BKM120, a pan-
class I PI3 kinase inhibitor, was investigated in a phase II non-
randomized study of BKM120 with or without enzalutamide in
men with progressive mCRPC who failed or were not candi-
dates for docetaxel chemotherapy [13]. Thirteen of 30 (43%)
patients received BKM120 while continuing enzalutamide.
Of all patients treated, treatment was not well tolerated (47%
of patients experienced grade 3 adverse events), and no
patient achieved >50% PSA response or objective response
ASSESSMENT, ANALYSIS, AND DISCUSSION
Completion Study terminated before completion
Terminated reason Toxicity
Pharmacokinetics/Pharmacodynamics Not collected—pharmacokinetics studies were not performed because
the study was terminated early.
Investigator’s Assessment Poorly tolerated/not feasible
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[13]. More recently, results of a randomized phase II study
of ipatasertib (GDC-0068), an AKT inhibitor, combined with
abiraterone/prednisone in men with docetaxel-pretreated
mCRPC, were presented [14). In this study, 253 patients were
randomized to ipatasertib 200 mg daily, ipatasertib 400 mg
daily, or placebo in combination with standard dose abirater-
one. A trend toward improved radiographic progression-free
survival (hazard ratio (HR)5 0.75, p5 .17) and overall survival
(HR5 0.72, p5 .22) was observed with ipatasertib 400 mg
daily plus abiraterone, but not ipatasertib 200 mg daily plus
abiraterone, indicating a dose response. Importantly, adverse
events were also dose dependent, and this combination was
well tolerated with manageable side effects. AKT inhibitors lie
at an important signaling junction—downstream of PI3K and
upstream of mTOR—and may have a better therapeutic index
compared with agents such as BEZ235.
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FIGURES AND TABLES
Figure 2. Percentage PSA change from baseline during study
period for patients who received at least 1 month of study treat-
ment. The longest treatment break was 12 days in patient 2.
Abbreviation: PSA, prostate-specific antigen.
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Table 2. Baseline demographic and disease characteristics
Characteristic
Abiraterone/Prednisonea
1 BEZ235 200 mg b.i.d. (n5 6)
Patients, no. 6
Age, year
Median (range) 71 (59–75)
Race, no. (%)
White 4 (66.7)
Black 1 (!6.7)
Asian 1 (16.7)
ECOG performance status, no. (%)
0 4 (66.7)
1 2 (33.3)
Gleason score, no. (%)
4–6 1 (16.7)
7 0 (0)
8–10 5 (83.3)
Site of metastasis, no. (%)
Node only 0 (0)
Bone only 4 (66.7)
Bone1 node 2 (33.3)
Visceral 0 (0.0)
Prior treatment for mCRPC, no. (%)
Abiraterone acetate 6 (100.0)
Ketoconazole 4 (66.7)
Sipuleucel-T 1 (16.7)
Enzalutamide 0 (0.0)
Radium-223 0 (0.0)
Chemotherapy 0 (0.0)
PSA, ng/mL
Median (range) 110.5 (26.7–233.6)
LDH, U/L
Median (range) 218.5 (171.0–345.0)
Hematocrit, g/dL
Median (range) 36.6 (31.8–39.6)
Alkaline phosphatase, U/L
Median (range) 86.5 (51.0–493.0)
aAbiraterone dose: 1,000 mg daily with prednisone 5 mg b.i.d.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; mCRPC, metastatic castration resistant prostate cancer;
PSA, prostate specific antigen.
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Table 4. Treatment duration and reason off study
Patient no. Treatment duration Off study reason Patient withdrawal
1 3 days AEs, including grade 3 oral mucositis and grade 1 diarrhea Yes
2 130 days Disease progression No
3 7 days AEs, including grade 2 oral mucositis and grade 1
anal mucositis
Yes
4 112 days AEs, including grade 1 anorexia, grade 1 dyspepsia,
and grade 1 emesis
Yes
5 38 days AEs, specifically grade 4 dyspnea and pneumonitis
requiring hospitalization (resolved after steroids)
Yes
6 16 days AEs, including grade 3 hypotension, grade 2 anorexia,
grade 2 oral mucositis, and grade 2 diarrhea
Yes
Abbreviation: AE, adverse event.
Click here to access other published clinical trials.
Table 3. Treatment-related adverse events
Adverse events
Abiraterone/Prednisone* 1 BEZ235 200 mg b.i.d. (n5 6)
Grade 1–2, n (%) Grade 3, n (%) Grade 4, n (%)
Any event 6 (100.0) 2 (33.3) 1 (16.7)
Oral mucositis 4 (66.7) 1 (16.7) 0 (0.0)
Diarrhea 4 (66.7) 0 (0.0) 0 (0.0)
Nausea 3 (50.0) 0 (0.0) 0 (0.0)
Anorexia 3 (50.0) 0 (0.0) 0 (0.0)
Weight loss 3 (50.0) 0 (0.0) 0 (0.0)
Musculoskeletal pain 3 (50.0) 0 (0.0) 0 (0.0)
Fatigue 2 (33.3) 0 (0.0) 0 (0.0)
Rash 2 (33.3) 0 (0.0) 0 (0.0)
Adverse events were graded by CTCAE v4.0. Patients were classified according to the worst grade of adverse event(s) reported. Adverse events
occurring in more than 1 patient (>16.7%) are shown. *Abiraterone dose: 1,000 mg daily with prednisone 5 mg b.i.d.
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